Suppr超能文献

局部复发对接受新辅助化疗的肢体骨肉瘤患者生存的影响:一家机构对44例患者的经验。

Influence of local recurrence on survival in patients with extremity osteosarcoma treated with neoadjuvant chemotherapy: the experience of a single institution with 44 patients.

作者信息

Bacci Gaetano, Longhi Alessandra, Cesari Marilena, Versari Michela, Bertoni Franco

机构信息

Division of Chemotherapy, Institute Ortopedico Rizzoli, Bologna, Italy.

出版信息

Cancer. 2006 Jun 15;106(12):2701-6. doi: 10.1002/cncr.21937.

Abstract

BACKGROUND

Risk factors for local recurrence (LR) after osteosarcoma, such as surgical margins and histologic response to preoperative treatment, have been well documented, whereas the outcome for patients who locally recur has not been well established yet.

METHODS

Retrospective analysis of the management and outcome of 44 patients who developed LR after treatment of osteosarcoma of the extremities with neoadjuvant chemotherapy was performed in a single institution between 1983 and 1999.

RESULTS

In 24 patients (54.5%), LR was the first sign of recurrence; in 8 patients (18.2%) LR followed systemic recurrence and in 12 patients (27.3%), the 2 events, local and systemic recurrence, were concurrent. Of the 44 patients, 26 with local recurrences were free of disease, but only 5 were long-term event-free survivors, and 39 patients developed further recurrences: 37 died of the tumor and 2 were alive with uncontrolled disease at the time of last follow-up. The 5-year disease-free survival rate after the last recurrence was 15.9%; it was 25.9% for patients who achieved remission and 0% for the others. The only prognostic factor identified for post-LR disease-free survival was the presence of systemic recurrence at the time of diagnosis of LR or before (5-year postrecurrence event-free survival rate of 29.1% for patients without metastases at the time of local recurrence vs. 0% for those with metastases; P = .02).

CONCLUSIONS

These results confirm that patients with osteosarcoma of the extremities who develop LR are at a very significantly high risk of developing metastatic disease and dying of the tumor.

摘要

背景

骨肉瘤局部复发(LR)的危险因素,如手术切缘和对术前治疗的组织学反应,已有充分记录,而局部复发患者的预后尚未明确。

方法

对1983年至1999年在单一机构接受新辅助化疗治疗四肢骨肉瘤后发生LR的44例患者的治疗及预后进行回顾性分析。

结果

24例患者(54.5%)中,LR是复发的首发症状;8例患者(18.2%)LR发生在全身复发之后,12例患者(27.3%)局部和全身复发同时发生。44例患者中,26例局部复发患者无疾病,但只有5例是长期无事件生存者,39例患者出现进一步复发:37例死于肿瘤,2例在最后随访时仍患有未控制的疾病存活。最后一次复发后的5年无病生存率为15.9%;缓解患者为25.9%,其他患者为0%。确定的LR后无病生存的唯一预后因素是在诊断LR时或之前存在全身复发(局部复发时无转移患者的5年复发后无事件生存率为29.1%,有转移患者为0%;P = 0.02)。

结论

这些结果证实,发生LR的四肢骨肉瘤患者发生转移性疾病和死于肿瘤的风险非常高。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验